CDTX Cidara Therapeutics, Inc.

7.10
0  -1%
Previous Close 7.15
Open 7.15
Price To book 1.35
Market Cap 118.38M
Shares 16,673,000
Volume 258,551
Short Ratio 3.38
Av. Daily Volume 77,969

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated June 2016. Data due 4Q 2017.
CD101 IV - STRIVE
Candidemia
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)

Latest News

  1. CIDARA THERAPEUTICS, INC. Financials
  2. Cidara Therapeutics reports 4Q loss
  3. Cidara Therapeutics reports 4Q loss
  4. Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
  5. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  6. Is The Cidara Therapeutics Inc (CDTX) Crash An Opportunity?
  7. Cidara Yeast Infection Gelm Fails Phase 2 Trial
  8. Cidara Therapeutics upgraded by WBB Securities
  9. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi
  10. Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
  11. Antimicrobials Working Group Announces New Leadership Team
  12. CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  13. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  14. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  15. Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
  16. Hedge Funds Aren’t Crazy About Cidara Therapeutics Inc (CDTX) Anymore
  17. Cidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  18. Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
  19. Is Cidara Therapeutics (CDTX) Stock a Solid Choice Right Now?
  20. Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results